Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

Aratana Therapeutics Reports First Quarter 2016 Financial Results

May 5, 2016 4:06 PM EDT

LEAWOOD, Kan., May 5, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter ended March 31, 2016, Aratana reported a net loss of $18.1 million or $0.52 basic loss per share.

"We have accomplished significant milestones in the first quarter with our first FDA approval, followed by sequentially filing for marketing approval in Europe and filing for FDA approval of our second therapeutic candidate," stated Steven St.... More